Hydrogen oxygen therapy is a form of inhalation therapy that delivers a mixture of molecular hydrogen (H2) and oxygen (O2) gases, typically in a 2:1 ratio. Sometimes called Brown’s gas, HHO gas, or oxyhydrogen therapy, it gained significant attention during the COVID-19 pandemic when Chinese researchers, including pulmonologist Zhong Nanshan, investigated it for respiratory distress. The therapy is distinct from hyperbaric oxygen therapy (HBOT) and operates through entirely different mechanisms, primarily targeting oxidative stress and inflammation through hydrogen’s selective antioxidant properties.
This guide explains what hydrogen oxygen therapy actually is, separates the science from the marketing, reviews the clinical evidence, and covers practical details like devices, costs, and safety.
Key Takeaways
- Hydrogen oxygen therapy delivers a 66% H2 / 33% O2 gas mixture via nasal cannula at normal atmospheric pressure
- Molecular hydrogen acts as a selective antioxidant, neutralizing hydroxyl radicals (OH·) and peroxynitrite (ONOO-) while preserving beneficial reactive oxygen species1
- China’s National Health Commission included H2/O2 inhalation in its COVID-19 treatment guidelines based on research led by Zhong Nanshan2
- A multicenter RCT of 144 COVID-19 patients showed improved dyspnea and disease severity scores with H2/O2 inhalation2
- Evidence for non-COVID conditions (cancer, COPD, neurodegenerative disease) is limited to preclinical studies and small pilot trials
- Home devices cost $2,000 to $6,000; clinical sessions run $50 to $150 per session
What Is Hydrogen Oxygen Therapy?
Hydrogen oxygen therapy uses an electrolyzer to split water (H2O) into its component gases: hydrogen and oxygen. The resulting gas mixture, approximately 66% hydrogen and 33% oxygen by volume, is delivered to the patient through a nasal cannula at atmospheric pressure. Flow rates typically range from 300 mL/min to 3,000 mL/min depending on the device.
The therapy goes by several names:
- Brown’s gas (after Yull Brown, who popularized electrolytic gas generation)
- HHO gas (referring to the 2:1 hydrogen-to-oxygen ratio)
- Oxyhydrogen therapy
- Hydrogen inhalation therapy (when referring to the hydrogen component specifically)
It is fundamentally different from HBOT in every way that matters:
| Feature | Hydrogen Oxygen Therapy | HBOT |
|---|---|---|
| Gas | 66% H2 + 33% O2 | 100% O2 |
| Pressure | 1.0 ATA (normal) | 1.5 to 3.0 ATA |
| Delivery | Nasal cannula | Pressurized chamber |
| Primary mechanism | Selective antioxidant (hydrogen) | Hyperoxygenation |
| Session setting | Open room, at home or clinic | Sealed hyperbaric chamber |
| Cost per session | $50 to $150 (or home device) | $150 to $350+ |
How Molecular Hydrogen Works in the Body
The therapeutic interest in hydrogen gas began with a landmark 2007 paper by Ohsawa et al. published in Nature Medicine. The study demonstrated that hydrogen gas selectively reduces hydroxyl radicals (OH·) and peroxynitrite (ONOO-), the two most cytotoxic reactive oxygen species, while leaving beneficial signaling molecules like hydrogen peroxide (H2O2) and nitric oxide (NO) intact.1
This selectivity is the key differentiator. Traditional antioxidants like vitamin C or E neutralize reactive oxygen species indiscriminately, which can interfere with normal cellular signaling. Hydrogen targets only the most destructive radicals.
Proposed mechanisms of action include:
- Selective antioxidant activity: Neutralizes hydroxyl radicals and peroxynitrite
- Anti-inflammatory signaling: Downregulates NF-κB and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
- Nrf2 pathway activation: Upregulates endogenous antioxidant enzymes
- Mitochondrial protection: Reduces oxidative damage to mitochondrial membranes and DNA
- Cell signaling modulation: Influences gene expression related to inflammation and apoptosis
Hydrogen is the smallest molecule in existence. It diffuses rapidly through cell membranes, crosses the blood-brain barrier, and reaches intracellular compartments including mitochondria and nuclei. This penetration ability gives it access to sites that many drugs cannot reach.
The COVID-19 Research
Hydrogen oxygen therapy received its highest-profile endorsement during the COVID-19 pandemic. In early 2020, Chinese pulmonologist Zhong Nanshan, one of China’s most prominent medical figures, led research into H2/O2 inhalation for COVID-19 patients with respiratory distress.
Guan et al. (2020) conducted a multicenter, open-label RCT of 144 patients with mild to moderate COVID-19. Patients received either standard oxygen therapy or H2/O2 mixed gas (66% H2, 33% O2) at 3 L/min via nasal cannula. The H2/O2 group showed significantly improved dyspnea scores, cough severity, and disease severity compared to controls.2
“H2-O2 inhalation ameliorated disease severity from baseline to day 7 compared with control treatment in patients with COVID-19.”
Guan et al., 2023, Journal of Thoracic Disease
Based on this and related research, China’s National Health Commission included H2/O2 inhalation in its official COVID-19 treatment protocols. However, it is important to note that:
- The study was open-label (not blinded), which introduces potential bias
- The improvement was in symptom scores, not hard outcomes like mortality or ICU admission
- No other national health authority adopted the recommendation
- The findings have not been replicated in large Western trials
Evidence for Other Conditions
Beyond COVID-19, hydrogen therapy research spans a wide range of conditions. The evidence varies significantly:
| Condition | Evidence Level | Key Findings |
|---|---|---|
| COVID-19 respiratory symptoms | Moderate (1 RCT) | Improved dyspnea and disease severity scores |
| Cancer (adjunct to treatment) | Preclinical + pilot | Reduced radiation side effects in some pilot studies; animal data on tumor growth inhibition |
| Exercise performance | Limited (small RCTs) | Reduced lactate levels; mixed results on performance metrics |
| Parkinson’s disease | Preclinical + 1 pilot | Neuroprotective effects in animal models; small human pilot showed improved symptoms |
| Metabolic syndrome | Limited (small trials) | Improved lipid profiles and insulin sensitivity in hydrogen-rich water studies |
| COPD | Preclinical | Reduced airway inflammation in animal models |
An important caveat: much of the hydrogen therapy research uses hydrogen-rich water (drinking) or hydrogen gas inhalation alone, not the H2/O2 mixed gas that defines “hydrogen oxygen therapy.” Results from one delivery method do not automatically apply to another.
Devices and Home Use
Unlike HBOT, hydrogen oxygen therapy can be administered at home using commercially available electrolysis devices. These units plug into a standard outlet, use distilled water as feedstock, and produce H2/O2 gas delivered through a nasal cannula.
Key specifications to look for:
- Flow rate: 300 mL/min (entry-level) to 3,000 mL/min (clinical-grade)
- Hydrogen purity: 99.99% or higher from the electrolysis cell
- Safety features: Automatic shutoff, water level sensors, overheat protection
- Water reservoir capacity: Determines continuous run time
Home devices typically cost $2,000 to $6,000 depending on flow rate and build quality. Clinical-grade units with higher flow rates can cost $8,000 to $15,000. Sessions at clinics run $50 to $150 per session, with typical recommendations of 30 to 60 minutes daily.
Safety
Hydrogen gas has a strong safety profile at therapeutic concentrations. The explosive limit of hydrogen in air is 4.6%, while therapeutic inhalation concentrations typically stay below 4%. The H2/O2 mixture from electrolysis devices does contain hydrogen above the explosive limit, but the low flow rates and immediate dilution during inhalation minimize ignition risk. Still, devices should never be used near open flames or sparks.
Reported side effects in clinical studies are minimal: occasional mild nausea, headache, or nasal dryness. No serious adverse events have been attributed to hydrogen inhalation in published clinical trials.3
Hydrogen gas does not accumulate in the body. Excess hydrogen is exhaled within minutes of stopping inhalation.
The Bottom Line
Hydrogen oxygen therapy is a real treatment with a legitimate scientific basis, but the clinical evidence is still early-stage for most conditions. The strongest human data comes from the COVID-19 research in China, which showed symptomatic improvement but has not been replicated in large Western trials. The selective antioxidant mechanism described by Ohsawa in 2007 is well-established in preclinical research, and over 1,500 scientific papers on hydrogen therapy have been published. But preclinical promise does not always translate to clinical benefit.
For patients interested in hydrogen oxygen therapy, it represents a low-risk intervention with plausible mechanisms and emerging evidence. It should not replace proven treatments for any condition, but it may complement existing therapies, particularly for conditions involving oxidative stress and chronic inflammation.
References
- Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13(6):688-694. doi:10.1038/nm1577
- Guan WJ, Wei CH, Chen AL, et al. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J Thorac Dis. 2020;12(6):3448-3452. doi:10.21037/jtd-2020-057
- Ge L, Yang M, Yang NN, et al. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. Oncotarget. 2017;8(60):102653-102673. doi:10.18632/oncotarget.21130
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
